Immune to Cancer: The CRI Blog
-
FDA Approves Expanded Use of Nivolumab for Lung Cancer
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…
-
FDA Approves PD-1 Immunotherapy for Most Common Type of Lung Cancer
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
-
In a First, FDA Approves Immunotherapy Combination for Advanced Melanoma
The approval of a combination of two immunotherapy drugs for melanoma represents a treatment milestone.
-
New Study: Vaccine Holds Promise in Treating Cervical Pre-Cancer
The vaccine could provide a new treatment option for patients with high-risk cervical pre-cancer.
-
Clinton and Cuomo Applaud the Work of CRI Scientists at Annual Awards Dinner
The two politicians were united in their support for the work done by cancer immunotherapy researchers.
-
Love Is On
Share the love with CRI in the Revlon LOVE IS ON Million Dollar Challenge.
-
CICON15 Report from Day 4
Highlights from the final day of the inaugural International Cancer Immunotherapy Conference.
-
CICON15 Report from Day 3
Highlights from Day 3 of the inaugural International Cancer Immunotherapy Conference.
-
CICON15 Report from Day 2
Highlights from Day 2 of the inaugural International Cancer Immunotherapy Conference.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.